Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging

Are dilution, slow injection and care bolus technique the causal solution to mitigating arterial-phase artifacts on gadoxetic acid-enhanced MRI? A large-cohort study

OBJECTIVE

Arterial-phase artifacts are gadoxetic acid (GA)-enhanced MRI's major drawback, ranging from 5 to 39%. We evaluate the effect of dilution and slow injection of GA using automated fluoroscopic triggering on liver MRI arterial-phase (AP) acquisition timing, artifact frequency, and lesion visibility.

METHODS AND MATERIALS

Saline-diluted 1:1 GA was injected at 1 ml/s into 1413 patients for 3 T liver MRI. Initially, one senior abdominal radiologist, i.e., principal investigator (PI), assessed all MR exams and compared them to previous and follow-up images, as well as the radiology report on record, determining the standard of reference for lesion detection and characterization. Then, three other readers independently evaluated the AP images for artifact type (truncation (TA), transient severe motion (TSM) or mixed), artifact severity (on a 5-point scale), acquisition timing (on a 4-point scale) and visibility (on a 5-point scale) of hypervascular lesions ≥ 5 mm, selected by the PI. Artifact score ≥ 4 and artifact score ≤ 3 were considered significant and non-significant artifacts, respectively.

RESULTS

Of the 1413 exams, diagnostic-quality arterial-phase images included 1100 (77.8%) without artifacts, 220 (15.6%) with minimal, and 77 (5.4%) with moderate artifacts. Only 16 exams (1.1%) had significant artifacts, 13 (0.9%) with severe artifacts (score 4), and three (0.2%) non-diagnostic artifacts (score 5). AP acquisition timing was optimal in 1369 (96.8%) exams. Of the 449 AP hypervascular lesions, 432 (96.2%) were detected.

CONCLUSION

Combined dilution and slow injection of GA with MR results in well-timed arterial-phase images in 96.8% and a reduction of exams with significant artifacts to 1.1%.

CLINICAL RELEVANCE STATEMENT

Hypervascular lesions, in particular HCC detection, hinge on arterial-phase hyperenhancement, making well-timed, artifact-free arterial-phase images a prerequisite for accurate diagnosis. Saline dilution 1:1, slow injection (1 ml/s), and automated bolus triggering reduce artifacts and optimize acquisition timing.

KEY POINTS

• There was substantial agreement among the three readers regarding the presence and type of arterial-phase (AP) artifacts, acquisition timing, and lesion visibility. • Impaired AP hypervascular lesion visibility occurred in 17 (3.8%) cases; in eight lesions due to mistiming and in nine lesions due to significant artifacts. • When AP timing was suboptimal, it was too late in 40 exams (3%) and too early in 4 exams (0.2%) of exams.

Fully automatic quantification of transient severe respiratory motion artifact of gadoxetate disodium-enhanced MRI during arterial phase

PURPOSE

It is important to fully automate the evaluation of gadoxetate disodium-enhanced arterial phase images because the efficient quantification of transient severe motion artifacts can be used in a variety of applications. Our study proposes a fully automatic evaluation method of motion artifacts during the arterial phase of gadoxetate disodium-enhanced MR imaging.

METHODS

The proposed method was based on the construction of quality-aware features to represent the motion artifact using MR image statistics and multidirectional filtered coefficients. Using the quality-aware features, the method calculated quantitative quality scores of gadoxetate disodium-enhanced images fully automatically. The performance of our proposed method, as well as two other methods, was acquired by correlating scores against subjective scores from radiologists based on the 5-point scale and binary evaluation. The subjective scores evaluated by two radiologists were severity scores of motion artifacts in the evaluation set on a scale of 1 (no motion artifacts) to 5 (severe motion artifacts).

RESULTS

Pearson's linear correlation coefficient (PLCC) and Spearman's rank-ordered correlation coefficient (SROCC) values of our proposed method against the subjective scores were 0.9036 and 0.9057, respectively, whereas the PLCC values of two other methods were 0.6525 and 0.8243, and the SROCC values were 0.6070 and 0.8348. Also, in terms of binary quantification of transient severe respiratory motion, the proposed method achieved 0.9310 sensitivity, 0.9048 specificity, and 0.9200 accuracy, whereas the other two methods achieved 0.7586, 0.8996 sensitivities, 0.8098, 0.8905 specificities, and 0.9200, 0.9048 accuracies CONCLUSIONS: This study demonstrated the high performance of the proposed automatic quantification method in evaluating transient severe motion artifacts in arterial phase images.

Gadoxetate disodium-enhanced MRI: Assessment of arterial phase artifacts and hepatobiliary uptake in a large series

PURPOSE

To report the quality of gadoxetate disodium MRI in a large series by assessing the prevalence of: 1) arterial phase (AP) artifacts and its predictive factors, 2) decreased hepatic contrast uptake during the hepatobiliary phase (HBP).

METHODS

This retrospective single center study included 851 patients (M/F:537/314, mean age: 63y) with gadoxetate disodium MRI. The MRI protocol included unenhanced, dual arterial [early and late arterial phases (AP)], portal venous, transitional and hepatobiliary phases. Three radiologists graded dynamic images using a 5-scale score (1: no motion, 5: severe, nondiagnostic) for assessment of transient severe motion (TSM, defined as a score ≥4 during at least one AP with a score ≤3 during other phases). HBP uptake was assessed using a 3-scale score (based on portal vein/hepatic signal). The association between demographic, clinical and acquisition parameters with TSM was tested in uni- and multivariate logistic regression.

RESULTS

TSM was observed in 103/851 patients (12.1 %): 83 (9.8 %) in one AP and 20 (2.3 %) in both APs. A score of 5 (nondiagnostic) was assigned in 7 patients in one AP (0.8 %) and none in both. Presence of TSM was significantly associated with age (p = 0.002) and liver disease (p = 0.033) in univariate but not in multivariate analysis (p > 0.05). No association was found between acquisition parameters and TSM occurrence. Limited or severely limited HBP contrast uptake was observed in 87 patients (10.2 %), and TSM was never associated with severely limited HBP contrast uptake.

CONCLUSION

TSM was present in approximately 12 % of gadoxetate disodium MRIs, rarely on both APs (2.3 %), and was poorly predicted. TSM was never associated with severely limited HBP contrast uptake.

Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study

PURPOSE

To identify predictive factors for truncation artifacts (TAs) in the arterial phase of Gd-EOB-DTPA-enhanced MRI in a multicenter study in Japan.

MATERIALS AND METHODS

Data on patient factors (age, sex, weight, presence of viral hepatitis, and other conditions) and imaging parameters (e.g., triggering, voxel size, matrix, k-space ordering, acquisition time, reduction factor, flip angle, fat suppression, field strength, injection rate, and saline volume) were obtained. Univariate and multivariate analyses were performed to investigate the correlation of these parameters.

RESULTS

We evaluated 1444 patients from 43 institutions who were scanned using GE, Siemens, Philips, or Toshiba MRI equipment (501, 354, 349, and 240 patients, respectively). The total incidence of TAs was 12.5% (17.2, 3.6, 15.7, and 12.1%, respectively). The matrix [odds ratio (OR) 0.13], flip angle (OR 5.77), use of fat suppression (OR 0.106), and field strength (OR 0.092) used in the Philips equipment significantly increased the incidence of TAs in MRI examination.

CONCLUSIONS

The incidence of TAs in the arterial phase is influenced by several patient factors and imaging parameters. Especially, Siemens and Toshiba equipment had a significantly lower frequency of TAs. This indicates that such vendor-specific technology used in the dynamic sequence may have a TA-resistant effect.

The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor

OBJECTIVES

To compare the diagnostic accuracy of dynamic contrast-enhanced phases, hepatobiliary phase (HBP), and diffusion-weighted imaging (DWI) for the detection of liver metastases from neuroendocrine tumor (NET).

METHODS

Sixty-seven patients with suspected NET liver metastases underwent gadoxetic acid-enhanced MRI. Three radiologists read four imaging sets separately and independently: DWI, T2W+dynamic, T2WI+HBP, and DWI+HBP. Reference standard included all imaging, histological findings, and clinical data. Sensitivity and specificity were calculated and compared for each imaging set. Interreader agreement was evaluated by intraclass correlation coefficient (ICC). Univariate logistic regression was performed to evaluate lesion characteristics (size, ADC, and enhancing pattern) associated to false positive and negative lesions.

RESULTS

Six hundred twenty-five lesions (545 metastases, 80 benign lesions) were identified. Detection rate was significantly higher combining DWI+HBP than the other imaging sets (sensitivity 86% (95% confidence interval (CI) 0.845-0.878), specificity 94% (95% CI 0.901-0.961)). The sensitivity and specificity of the other sets were 82% and 65% for DWI, 88% and 69% for T2WI, and 90% and 82% for HBP+T2WI, respectively. The interreader agreement was statistically higher for both HBP sets (ICC = 0.96 (95% CI 0.94-0.97) for T2WI+HBP and ICC = 0.91 (95% CI 0.87-0.94) for DWI+HBP, respectively) compared with that for DWI (ICC = 0.76 (95% CI 0.66-0.83)) and T2+dynamic (ICC = 0.85 (95% CI 0.79-0.9)). High ADC values, large lesion size, and hypervascular pattern lowered the risk of false negative.

CONCLUSION

Given the high diagnostic accuracy of combining DWI+HBP, gadoxetic acid-enhanced MRI is to be considered in NET patients with suspected liver metastases. Fast MRI protocol using T2WI, DWI, and HBP is of interest in this population.

KEY POINTS

• The combined set of diffusion-weighted (DW) and hepatobiliary phase (HBP) images yields the highest sensitivity and specificity for neuroendocrine liver metastasis (NELM) detection. • Gadoxetic acid should be the contrast agent of choice for liver MRI in NET patients. • The combined set of HBP and DWI sequences could also be used as a tool of abbreviated MRI in follow-up or assessment of treatment such as somatostatin analogs.

Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background

Gadoxetic acid-enhanced magnetic resonance imaging (MRI) plays important roles in diagnosis of hepatic lesions because of its superiority in the detectability of small lesions, its differentiation ability, and its utility for the early diagnosis of hepatocellular carcinoma (HCC). In HCC, expression of organic anion transporting polypeptide (OATP) 1B3 correlates with the enhancement ratio in the hepatobiliary phase. Gadoxetic acid-enhanced MRI, an indirect molecular imaging method, reflects OATP1B3 expression in HCC. OATP1B3 expression gradually decreases from the dysplastic nodule stage to advanced HCC. Decreased expression is a sensitive marker of multistep hepatocarcinogenesis, especially in the early stages. Hypervascular HCCs commonly show hypointensity in the hepatobiliary phase corresponding to a decrease in OATP1B3; however, approximately 10% of HCCs show hyperintensity due to OATP1B3 overexpression. This hyperintense HCC shows less aggressive biological features and has a better prognosis than hypointense HCC. Hyperintense HCC can be classified into a genetic subtype of HCC with a mature hepatocyte-like molecular expression. OATP1B3 expression and the less aggressive nature of hyperintense HCC are regulated by the molecular interaction of β-catenin signaling and hepatocyte nuclear factor 4α, a tumor suppressor factor. Gadoxetic acid-enhanced MR imaging has the potential to be an imaging biomarker for HCC. KEY POINTS: • The hepatobiliary phase is a sensitive indirect indicator of organic anion transporting polypeptide1B3 (OATP1B3) expression in hepatocellular carcinoma (HCC). • The OATP1B3 expression, namely, enhancement in the hepatobiliary phase, decreases from the very early stage of hepatocarcinogenesis, contributing to early diagnosis of HCC. • HCC showing hyperintensity on the hepatobiliary phase is a peculiar genetic subtype of HCC with OATP1B3 overexpression, a less aggressive nature, and mature hepatocyte-like molecular/genetic features.

Effects of gadoxetic acid on image quality of arterial multiphase magnetic resonance imaging of liver: comparison study with gadoteric acid-enhanced MRI

PURPOSE

To compare the effects of gadoxetic acid and gadoteric acid on the image quality of single-breath-hold, triple (first, second, and third) arterial hepatic magnetic resonance imaging (MRI).

METHODS

Two hundred and eleven patients were divided into two groups according to the contrast materials used (gadoxetic acid, 108 patients and gadoteric acid, 103 patients). All 3.0-T MR examinations included triple arterial phase acquisition using the 4D enhanced T1-weighted high-resolution isotropic volume examination (eTHRIVE) keyhole technique. The image qualities of the pre-contrast and triple arterial phases were assessed in terms of image artifacts, sharpness of the intrahepatic vessel and liver edge, and overall image quality with a 5-point scale for qualitative analysis.

RESULTS

The image quality of gadoxetic acid-enhanced liver MRI in the triple arterial phases was significantly degraded compared with that of gadoteric acid-enhanced liver MRI, although better image scores were observed in the pre-contrast images in the gadoxetic acid group (P < 0.001). The overall image quality gradually improved from the first to the third arterial phases in both groups (P < 0.003).

CONCLUSIONS

Intravenous gadoxetic acid could have a detrimental effect on image quality of triple arterial phase MRI with the 4D eTHRIVE Keyhole technique. The third arterial phase images had the best image qualities; thus, they could be used as key scans.

Relationship between the degree of abdominal wall movement and the image quality of contrast-enhanced MRI: semi-quantitative study especially focused on the occurrence of transient severe motion artifact

PURPOSE

To reveal the relationship between abdominal movement and artifact, and to reveal if the transient artifact in arterial phase is caused by transient abdominal movement (TAM) in contrast-enhanced (CE) MRI.

MATERIALS AND METHODS

325 CE-MRI series (206 with EOB and 119 with EGCM) were included. The abdominal movement was classified into three groups by respiratory bellows waveform (= bellows grade, BG 1-3), and MR image quality (= artifact score, AS) was graded 1-5 for the precontrast, arterial and portal venous phase, respectively. The relationship between the BG and AS was evaluated. The occurrence of transient artifact in arterial phase was compared to the degree of TAM.

RESULTS

In the acquisitions with BG3, all images showed AS of > 2, while no images had AS of > 4 in the acquisitions with BG1. Numbers of transient artifact in the arterial phase with no-abdominal movement (NAM), mild-TAM, severe-TAM were 0 of 120, 4 of 27, 7 of 8 in EOB and 0 of 91, 1 of 4, 0 of 0 in EGCM, respectively.

CONCLUSION

Image quality is highly correlated with abdominal movement. Moreover, artifact in arterial phase was not observed in NAM, which indicated abdominal movement is the direct cause of artifact.

Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid

OBJECTIVES

To evaluate the diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast agents (EC-MRI) vs. MRI with gadoxetic acid (EOB-MRI) for HCC detection in patients with liver cirrhosis using liver explant as the reference. The additional value of hepatobiliary phase (HBP) post Gadoxetic acid was also assessed.

METHODS

Two-hundred seventy-seven consecutive patients who underwent liver transplantation over a 9 year period and imaging within 90 days of were retrospectively included. Imaging consisted in CT (n = 100), EC-MRI (n = 77) and EOB-MRI (n = 100), the latter subdivided into dynamic EOB-MRI and full EOB-MRI (dynamic+HBP). Three radiologists retrospectively categorized lesions ≥ 1 cm using the LI-RADSv2017 algorithm. Dynamic EOB-MRI was re-evaluated with the addition of HBP. Results were correlated with explant pathology.

RESULTS

Pathology demonstrated 265 HCCs (mean size 2.1 ± 1.4 cm) in 177 patients. Per-patient sensitivities were 86.3% for CT, 89.5% for EC-MRI, 92.8% for dynamic EOB-MRI and 95.2% for full EOB-MRI (pooled reader data), with a significant difference between CT and dynamic/full EOB-MRI (p = 0.032/0.002), and between EC-MRI and full EOB-MRI (p = 0.047). Per-lesion sensitivities for CT, EC-MRI, dynamic EOB-MRI and full EOB-MRI were 59.5%,78.5%,69.7% and 76.8%, respectively, with a significant difference between MRI groups and CT (p-range:0.001-0.04), and no difference between EC-MRI and dynamic EOB-MRI (p = 0.949). For HCCs 1-1.9 cm, sensitivities were 34.4%, 64.6%, 57.3% and 67.3%, respectively, with all MRI groups significantly superior to CT (p ≤ 0.01) and full EOB-MRI superior to dynamic EOB-MRI (p = 0.002).

CONCLUSIONS

EOB-MRI outperforms CT and EC-MRI for per-patient HCC detection sensitivity, and is equivalent to EC-MRI for per-lesion sensitivity. MRI methods outperform CT for detection of HCCs 1-1.9 cm.

KEY POINTS

• MRI is superior to CT for HCC detection in patients with liver cirrhosis. • EOB-MRI outperforms CT and MRI using extracellular contrast agents (EC-MRI) for per-patient HCC detection sensitivity, and is equivalent to EC-MRI for per-lesion sensitivity. • The addition of hepatobiliary phase images improves HCC detection when using gadoxetic acid.

Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis

Purpose

To describe the clinical characteristics and outcomes of patients with dual-phenotype hepatocellular carcinoma (DPHCC) and investigate the use of radiomics to establish an image-based signature for preoperative differential diagnosis.

Methods

This study included 50 patients with a postoperative pathological diagnosis of DPHCC (observation group) and 50 patients with CK7- and CK19-negative HCC (control group) who attended our hospital between January 2015 and December 2018. All patients underwent Gd-EOB-DTPA-enhanced MRI within 1 month before surgery. Arterial phase (AP), portal venous phase (PVP), delayed phase (DP) and hepatobiliary phase (HBP) images were transferred into a radiomics platform. Volumes of interest covered the whole tumor. The dimensionality of the radiomics features were reduced using LASSO. Four classifiers, including multi-layer perceptron (MLP), support vector machines (SVM), logistic regression (LR) and K-nearest neighbor (KNN) were used to distinguish DPHCC from CK7- and CK19-negative HCC. Kaplan–Meier survival analysis was used to assess 1-year disease-free survival (DFS) and overall survival (OS) in the observation and control groups.

Results

The best preoperative diagnostic power for DPHCC will likely be derived from a combination of different phases and classifiers. The sensitivity, specificity and accuracy of LR in PVP (0.740, 0.780, 0.766), DP (0.893, 0.700, 0.798), HBP (0.800, 0.720, 0.756) and MLP in PVP (0.880, 0.720, 0.798) were better performance. The 1-year DFS and OS of the patients in the observation group were 69% and 78%, respectively. The 1-year DFS and OS of the patients in the control group were 83% and 85%, respectively. Kaplan–Meier survival analysis showed no statistical difference in DFS and OS between groups (P = 0.231 and 0.326), but DFS and OS were numerically lower in patients with DPHCC.

Conclusion

The radiomics features extracted from Gd-EOB-DTPA-enhanced MR images can be used to diagnose preoperative DPHCC. DPHCC is more likely to recur and cause death than HCC, suggesting that active postoperative management of patients with DPHCC is required.

[The Influence of the Decrease in Data Acquisition Ratio Resulted from Readout Partial Fourier during Readout Segmented EPI on ADC Map: A Phantom Study]

Readout segmented echo planar imaging (readout segmentation of long variable echo-trains, RESOLVE) is a method of dividing the k-space in the readout direction and sampling signals from multiple shots. Compared to the conventional single-shot echo planar imaging, echo space is shortened by dividing, and distortion of images is reduced, but there is a disadvantage that the imaging time is increased. To shorten the imaging time, readout partial Fourier (RPF) method was developed. In this study, it is evaluated how the apparent diffusion coefficient (ADC) value and uniformity of images are affected by RPF. In addition, signal intensity, noise, and signal-to-noise ratio of diffusion-weighted imaging were evaluated as factors influencing the ADC value and uniformity of images, and the artifacts of images were observed. When the data acquisition ratio decreased due to the RPF, the ADC value increased and the uniformity of images decreased. We had better to find special indices for the ADC map when we use RPF.

Experimental studies on artifacts and tumor enhancement on gadoxetic acid-enhanced arterial phase liver MRI in a rabbit VX2 tumor model

Background Rapid injection of gadoxetic acid is reported to produce more frequent artifacts and lower vascular enhancement on arterial phase liver magnetic resonance imaging (MRI). However, its effect on tumor enhancement and the mechanism of the artifacts remain unclear. Purpose To evaluate the effect of rapid injection of gadoxetic acid on artifacts and tumor enhancement during arterial phase liver MRI, and on arterial blood gases (ABGs) which may explain the cause of the artifacts. Material and Methods ABG analysis was performed in 13 free-breathing rabbits after rapid injection (1 mL/s; injection time = 0.6-0.8 s) of gadoxetic acid (0.025 mmol/kg). Dynamic liver MRI was performed in six anesthetized rabbits with VX2 tumors under a ventilation stoppage after rapid and slow injection (0.25 mL/s; injection time = 2.4-3.2 s) of gadoxetic acid. Artifacts and signal enhancement on arterial phase imaging were compared with those obtained after rapid injection of gadopentetic acid (Gd-DTPA, 0.1 mmol/kg) using a Friedman test or Kruskal-Wallis test. Results ABG analysis did not find any significant changes. Artifacts were not related to injection protocols ( P = 0.95). Aortic enhancement with slow injection of gadoxetic acid was significantly higher than that with rapid injection ( P < 0.05), and was comparable to that with Gd-DTPA injection. Tumor enhancement obtained with gadoxetic acid was not significantly different between rapid and slow injection, and was significantly lower than that with Gd-DTPA injection ( P < 0.05). Conclusion Rapid injection of gadoxetic acid did not affect ABGs and may not be the cause of the artifacts. It lowered vascular enhancement but not arterial tumor enhancement.

Mapping of hepatic vasculature in potential living liver donors: comparison of gadoxetic acid-enhanced MR imaging using CAIPIRINHA technique with CT angiography

PURPOSE

To retrospectively evaluate gadoxetic acid-enhanced magnetic resonance angiography (MRA) using controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) technique for mapping hepatic vascular anatomy in potential living liver donors, with CT angiography (CTA) as reference standard.

METHODS

82 potential living liver donors who underwent MRA and CTA were enrolled in this HIPAA-compliant IRB-approved study. MRA and CTA images were evaluated by two reviewers in consensus with respect to (1) image quality scores for depiction of the hepatic vessels and (2) accuracy of MRA for determining the hepatic vascular variants with CTA as reference standard. The image quality scores were compared using Fisher's exact test between MRA and CTA.

RESULTS

The accuracy for determining the hepatic arterial, portal, and hepatic venous variants and segment IV arterial origin was 73, 90, 79, and 55%, respectively, compared to CTA. However, subjective image quality for depiction of hepatic arteries in MRA was significantly lower than CTA (p < 0.001). The portal and hepatic venous image quality was almost equal in both modalities (p = 0.059) except left hepatic vein being depicted better on CT images (p = 0.023).

CONCLUSION

Gadoxetic acid-enhanced MRA using CAIPIRINHA technique is feasible for mapping hepatic vasculature in potential living liver donors, with moderate accuracy for arterial variants and good to excellent results for hepatic and portal vein variants, compared with CTA. However, the specific delineation of segment IV arterial origin was possible in just over half of the liver donors with MRA.

Influence of the reference scan and scan time on the arterial phase of liver magnetic resonance imaging

The controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) technique can decrease scan time. The purpose of this study was to determine whether an arterial phase scan can be performed in 5 s using the CAIPIRINHA short-scan and a reference scanning technique. The generalized autocalibrating partially parallel acquisition (GRAPPA), the CAIPIRINHA routine (CAIPI-routine), and the CAIPIRINHA short-scanning (CAIPI-short) methods were compared. The scan time for each method was preset to 20 s, 15 s, and 10 s, respectively. The reference scan had a scan time of 5 s. A phantom study was used to compare the influence of artifacts during the reference scan. For comparison, the phantom was moved during the last 5 s. In the clinical studies of suspected chronic liver diseases, magnetic resonance imaging of the liver is usually performed while the patient is breath-hold. The motion artifacts of each method were compared. Artifacts were reduced in reference scans using the CAIPIRINHA method. At 5 s after initiation, the rate of change in the standard deviation value was within 30% compared to that of the original image. Motion artifacts due to the influence of the reference scan when a patient failed to hold their breath did not complicate image evaluation. The proportion of motion artifacts for each sequence was as follows: GRAPPA, 5.8%; CAIPI-routine, 1.9%; and CAIPI-short, 0.7%. The arterial phase can be scanned in 5 s using the CAIPI-short and reference scan techniques.

Gadoxetate disodium-induced tachypnoea and the effect of dilution method: a proof-of-concept study in mice

OBJECTIVES

To directly investigate the rapid respiratory effect of gadoxetate disodium in an experimental study using mice.

METHODS

After confirming the steady respiratory state under general anaesthesia, eight mice were injected with all test agents in the following order: phosphate-buffered saline (A, control group), 1.25 mmol/kg of gadoteridol (B) or gadopentetate dimeglumine (C), or 0.31 mmol/kg of gadoxetate disodium (D, E). The experimenter was not blinded to the agents. The injection dose was fixed as 100 μL for Groups A-D and 50 μL for Group E. We continuously monitored and recorded respiratory rate (RR), peripheral oxygen saturation (SpO₂), and heart rate. The time-series changes from 0 to 30 s were compared by the linear mixed method RESULTS: Groups D and E showed the largest RR increase (20.6 and 20.3 breaths/min, respectively) and were significantly larger compared to Group A (3.36 breaths/min, both P<0.001). RR change of Groups D and E did not differ. RR change of Groups B and C was smaller (0.72 and 12.4 breaths/min, respectively) and did not differ statistically with Group A. Significant bradycardia was observed only in Group C (P<0.001). SpO₂ was constant in all groups.

CONCLUSIONS

Gadoxetate disodium causes a rapid tachypnoea without significant change of SpO₂ and heart rate regardless of the dilution method.

KEY POINTS

• Injection of gadoxetate disodium causes tachypnoea. • Dilution method did not alter the rapid respiratory effect of gadoxetate disodium. • The respiratory effect of gadoxetate disodium was larger than other contrast agents.

Comparison of the Timing of Hepatic Arterial Phase and Image Quality Using Test-Bolus and Bolus-Tracking Techniques in Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Hepatic Dynamic Magnetic Resonance Imaging

Objectives

The aim of this study was to compare the image quality, the degree of artifacts and the percentage of timing of the optimal hepatic arterial phase (HAP) between test-bolus and bolus-tracking methods on gadolinium–ethoxybenzyl–diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)–enhanced magnetic resonance imaging (MRI).

Methods

In this prospective study, 60 patients who underwent 3-dimensional dynamic Gd-EOB-DTPA–enhanced hepatic 3-T MRI were enrolled in this study. We randomly assigned the 30 patients to the bolus-tracking method, and another 30 patients to the test-bolus method. Signal-to-noise ratios of the liver and spleen in HAP were compared in the 2 groups. Two radiologists independently assessed the ratio of optimal timing of HAP and the degree of ringing and motion artifacts of the 2 protocols.

Results

The signal-to-noise ratios of the liver (24.0 [SD, 6.4] vs 20.4 [SD, 4.0]) and spleen (30.0 [SD, 13.3] vs 23.6 [SD, 9.9]) were significantly higher in the test-bolus protocol than in the bolus-tracking protocol. The ratio of optimal timing was also significantly higher with the test-bolus protocol than with the bolus-tracking protocol (76.7% vs 40.0%). The degree of ringing and motion artifacts of test-bolus protocol was significantly lower than that of the bolus-tracking protocol (P < 0.01).

Conclusions

The test-bolus protocol in dynamic 3-T MRI can yield better qualitative image quality and more optimal timing of HAP images, while reducing the degree of artifacts compared with the bolus-tracking protocol.

Reducing Artifacts during Arterial Phase of Gadoxetate Disodium-enhanced MR Imaging: Dilution Method versus Reduced Injection Rate

Purpose To compare two contrast material-administration protocols (dilution vs slow injection) in terms of their effectiveness in arterial phase artifact reduction at gadoxetic acid-enhanced magnetic resonance (MR) imaging. Materials and Methods This HIPAA-compliant retrospective case-controlled cohort study was approved by the institutional review board, with a waiver of informed patient consent. A total of 318 consecutive patients undergoing gadoxetic acid-enhanced MR imaging were placed into one of two subcohorts of 159 consecutive patients each: the dilution subcohort (gadoxetic acid was diluted 1:1 with saline and injected at a rate of 2.0 mL/sec) and the slow injection subcohort (gadoxetic acid was not diluted and was injected at a rate of 1.0 mL/sec). Eighty-nine patients in the dilution subcohort also underwent follow-up MR imaging with the slow injection method, and 34 patients in the slow injection subcohort underwent follow-up MR imaging with the dilution method. Both patient- and image-based analyses, as well as intraindividual analysis, were used to compare two parameters-mean artifact score rated by two observers using a five-point scale and frequency of severe artifact-between the dilution and slow injection subcohorts with the Wilcoxon Mann-Whitney test, χ² test, and generalized estimating equation. Results In both patient- and image-based analyses, the mean artifact score and frequency of severe artifact were lower in the dilution subcohort (mean, 1.46% and 3.8% [six of 159]) than in the slow injection subcohort (mean, 1.95% and 15.1% [24 of 159]) (P ≤ .001 and P < .001, respectively). In intraindividual analysis, both variables were also decreased in the dilution subcohort (P = .007 and P = .001, respectively). We found the two variables to be significantly increased in the slow injection subcohort when compared with that in the dilution subcohort for three different MR platforms (P < .05). Conclusion In comparison with slow injection of undiluted contrast material at a rate of 1.0 mL/sec, gadoxetic acid diluted to 50% and injected at a rate of 2 mL/sec had a significantly less severe ghosting artifact in the arterial phase of gadoxetic acid-enhanced MR imaging. ^© RSNA, 2016 Online supplemental material is available for this article.

MTF Measurement of MR Blurring in Liver Dynamic MRI with Gd-EOB-DTPA

During the arterial phase acquisition of Gd-EOB-DTPA examinations, use of a small volume of the Gd-EOB-DTPA may make it difficult the encoding center of the k-space, and produce blurring. The previous studies revealed the encoding technique of the k-space was one of the most important reasons. However, there is no report to discuss the reasons with quantitative evaluations. The purpose of this study was to quantitatively evaluate the characteristics of the artifacts using different k-space encoding techniques (centric-view ordering (CVO) and sequential-view ordering (SVO)) for liver dynamic MRI in computer simulation study. This simulation study consists of the following steps. First of all, the creation of a time intensity curve, and original simulation images at certain points among the one phase dynamic scanning. Secondly, creation-simulated MR echo data from the created original images using FFT, and encoding simulated k-space using the simulated MR echo data. Finally, a reconstruction of simulated dynamic MR images from the simulated k-space, and to evaluate each simulated MR images, we measured modulation transfer functions (MTFs) from the bar patterns of the reconstructed images. The results of the CVO simulation indicated that the bar patterns were blurring compared to the images encoded by the SVO. The results of the SVO simulation indicated that the bar patterns were not enhanced at late scan timings. In addition, the results of MTFs indicated that there was no edge enhancement at all scan timings and both encoding techniques. In conclusion, it is possible to quantitatively evaluate the characteristics of artifacts using MTF, which was measured by the bar patterns, in liver dynamic MRI.

Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging

Gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a unique hepatocyte-specific contrast agent approved for clinical use in the United States in 2008. Gd-EOB-DTPA-enhanced MR has shown to improve detection and characterization of hepatic lesions. Gd-EOB-DTPA is now being routinely used in daily clinical practice worldwide. Therefore, it is important for radiologists to be familiar with the potential uses and pitfalls of Gd-EOB-DTPA, which extends beyond the assessment of focal hepatic lesions. The purpose of this article is to review the various usages of Gd-EOB-DTPA in hepatobiliary MR imaging.

Shortened breath-hold contrast-enhanced MRI of the liver using a new parallel imaging technique, CAIPIRINHA (controlled aliasing in parallel imaging results in higher acceleration): a comparison with conventional GRAPPA technique

PURPOSE

We examined whether the shortened breath-hold 3-dimensional volumetric interpolated breath-hold examination (3D-VIBE) sequence for high acceleration factor (AF) using the controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) could substitute for the conventional sequence using generalized autocalibrating partially parallel acquisition (GRAPPA) in patients undergoing routine gadoxetic acid-enhanced liver MRI.

MATERIALS AND METHODS

Thirty patients with clinically suspected focal liver lesions were scanned using 3D-VIBE sequences with GRAPPA with AF = 2 and AF = 4 and CAIPIRINHA with AF = 4 (acquisition times: 21, 14, and 12 s, respectively) during the hepatobiliary phase. Visual evaluations using a 3- or 5-point scale and signal-to-noise ratio (SNR) analysis were performed for the 3 sequences.

RESULTS

For CAIPIRINHA with AF = 4, there was significantly less image noise in both visual evaluation and SNR analysis and fewer parallel imaging artifacts than for GRAPPA with AF = 4 (P < 0.0005); it was equal to GRAPPA with AF = 2 and had fewer motion artifacts than GRAPPA with AF = 2 and 4 (P < 0.0012). The liver edge sharpness and hepatic vessel clarity, lesion conspicuity, and overall image quality were rated significantly higher with CAIPIRINHA with AF = 4 than GRAPPA with AF = 2 and AF = 4 (P < 0.009). For GRAPPA with AF = 4, lesion conspicuity and overall image quality were rated significantly lower than for GRAPPA with AF = 2 (P < 0.012).

CONCLUSION

The shortened breath-hold 3D-VIBE sequence using the new CAIPIRINHA technique with a high AF of 4 was superior to the conventional GRAPPA sequence. The shortened breath-hold sequence using GRAPPA with a high AF of 4 worsened the image quality and lesion conspicuity.

Triple Arterial Phase MR Imaging with Gadoxetic Acid Using a Combination of Contrast Enhanced Time Robust Angiography, Keyhole, and Viewsharing Techniques and Two-Dimensional Parallel Imaging in Comparison with Conventional Single Arterial Phase

Objective

To determine whether triple arterial phase acquisition via a combination of Contrast Enhanced Time Robust Angiography, keyhole, temporal viewsharing and parallel imaging can improve arterial phase acquisition with higher spatial resolution than single arterial phase gadoxetic-acid enhanced magnetic resonance imaging (MRI).

Materials and Methods

Informed consent was waived for this retrospective study by our Institutional Review Board. In 752 consecutive patients who underwent gadoxetic acid-enhanced liver MRI, either single (n = 587) or triple (n = 165) arterial phases was obtained in a single breath-hold under MR fluoroscopy guidance. Arterial phase timing was assessed, and the degree of motion was rated on a four-point scale. The percentage of patients achieving the late arterial phase without significant motion was compared between the two methods using the χ² test.

Results

The late arterial phase was captured at least once in 96.4% (159/165) of the triple arterial phase group and in 84.2% (494/587) of the single arterial phase group (p < 0.001). Significant motion artifacts (score ≤ 2) were observed in 13.3% (22/165), 1.2% (2/165), 4.8% (8/165) on 1st, 2nd, and 3rd scans of triple arterial phase acquisitions and 6.0% (35/587) of single phase acquisitions. Thus, the late arterial phase without significant motion artifacts was captured in 96.4% (159/165) of the triple arterial phase group and in 79.9% (469/587) of the single arterial phase group (p < 0.001).

Conclusion

Triple arterial phase imaging may reliably provide adequate arterial phase imaging for gadoxetic acid-enhanced liver MRI.

Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Imaging is important for establishing a diagnosis of HCC and early diagnosis is imperative as several potentially curative treatments are available when HCC is small. Hepatocarcinogenesis occurs in a stepwise manner on a background of chronic liver disease or cirrhosis wherein multiple genes are altered resulting in a range of cirrhosis-associated nodules. This progression is related to increased cellularity, neovascularity and size of the nodule. An understanding of the stepwise progression may aid in early diagnosis. Dynamic and multiphase contrast-enhanced computed tomography and magnetic resonance imaging still form the cornerstone in the diagnosis of HCC. An overview of the current diagnostic standards of HCC in accordance to the more common practicing guidelines and their differences will be reviewed. Ancillary features contribute to diagnostic confidence and has been incorporated into the more recent Liver Imaging Reporting and Data System. The use of hepatocyte-specific contrast agents is increasing and gradually changing the standard of diagnosis of HCC; the most significant benefit being the lack of uptake in the hepatocyte phase in the earlier stages of HCC progression. An outline of supplementary techniques in the imaging of HCC will also be reviewed.

One-stop-shop preoperative evaluation for living liver donors with gadoxetic acid disodium-enhanced magnetic resonance imaging: efficiency and additional benefit

OBJECTIVE

To explore the efficiency, cost, and time for examination of one-stop-shop gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) in preoperative evaluation for parent donors by comparing with multidetector computer tomography combined with conventional MR cholangiopancreatography (MDCT-MRCP).

MATERIALS AND METHODS

Forty parent donors were evaluated with MDCT-MRCP, and the other 40 sex-, age-, and weight-matched donors with Gd-EOB-DTPA-enhanced MRI. Anatomical variations and graft volume determined by pre- and intra-operative findings, costs and time for imaging were recorded. Image quality was ranked on a 4-point scale and compared between both groups.

RESULTS

Gd-EOB-DTPA-enhanced MRI provided better image quality than MDCT-MRCP for the depiction of portal veins and bile ducts by both reviewers (p < 0.05), hepatic veins by one reviewer (p < 0.05), rather hepatic arteries by both reviewers (p < 0.01). Sixty-nine living donors proceeded to liver donation with all anatomical findings accurately confirmed by intra-operative findings. The "in-room" time of Gd-EOB-DTPA-enhanced MRI was 12 min longer than MDCT-MRCP. Gd-EOB-DTPA-enhanced MRI was cheaper than MDCT-MRCP (US$519.72 vs. US$631.85).

CONCLUSION

One-stop-shop Gd-EOB-DTPA-enhanced MRI has similar diagnostic accuracy as MDCT-MRCP and can provide additional benefit in terms of costs and convenience in preoperative evaluation for parent donors.

Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver

Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images. However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion. In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field.

An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging

PURPOSE

To investigate the cause of imaging artifacts observed during gadoxetic acid-enhanced arterial phase imaging of the liver.

MATERIALS AND METHODS

This HIPAA-compliant study was approved by the institutional review board. Data were collected prospectively at two sites (site A, United States; site B, Japan) from patients undergoing contrast material-enhanced MR imaging with gadoxetic acid (site A, n = 154, dose = 0.05 mmol/kg; site B, n = 130, 0.025 mmol/kg) or gadobenate dimeglumine (only site A, n = 1666) from January 2014 to September 2014 at site A and from November 2014 to January 2015 at site B. Detailed comparisons between the two agents were made in the patients with dynamic liver acquisitions (n = 372) and age-, sex-, and baseline oxygen saturation (Spo2)-matched pairs (n = 130) at site A. Acquired data included self-reported dyspnea after contrast agent injection, Spo2, and breath-hold fidelity monitored with respiratory bellows.

RESULTS

Self-reported dyspnea was more frequent with gadoxetic acid than with gadobenate dimeglumine (site A, 6.5% [10 of 154] vs 0.1% [two of 1666], P < .001; site B, 1.5% [two of 130]). In the matched-pair comparison, gadoxetic acid, as compared with gadobenate dimeglumine, had higher breath-hold failure rates (site A, 34.6% [45 of 130] vs 11.7% [15 of 130], P < .0001; site B, 16.2% [21 of 130]) and more severe artifacts during arterial phase imaging (site A, 7.7% [10 of 130] vs 0% [none of 130], P < .001; site B, 2.3% [three of 130]). Severe imaging artifacts in patients who received gadoxetic acid were significantly associated with male sex (P = .023), body mass index (P = .021), and breath-hold failure (P < .001) but not with dyspnea or Spo2 decrease.

CONCLUSION

Severe motion-related artifacts in the arterial phase of gadoxetic acid-enhanced liver MR imaging are associated with breath-hold failure but not with subjective feelings of dyspnea or a substantial decrease in blood Spo2. Subjective feelings of dyspnea are not necessarily associated with imaging artifacts. The phenomenon, albeit at a lower rate, was confirmed at a second site in Japan.

Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging

Objectives

Liver-specific MRI is a fast-growing field, with technological and protocol advancements providing more robust imaging and allowing a greater depth of information per examination. This article reports the evidence for, and expert thinking on, current challenges in liver-specific MRI, as discussed at the 7th International Forum for Liver MRI, which was held in Shanghai, China, in October 2013.

Methods

Topics discussed included the role of gadoxetic acid-enhanced MRI in the differentiation of focal nodular hyperplasia from hepatocellular adenoma and small hepatocellular carcinoma (HCC) from small intrahepatic cholangiocarcinoma (in patients with chronic liver disease), the differentiation of low-grade dysplastic nodule (DN) from pre-malignant high-grade DN and early HCC, and treatment planning and assessment of treatment response for patients with HCC and colorectal liver metastasis. Optimization of the gadoxetic acid-enhanced MRI protocol to gain robust arterial and hepatobiliary phase images was also discussed.

Results and conclusions

Gadoxetic acid-enhanced MRI demonstrates added value for the detection and characterization of focal liver lesions and shows promise in a number of new indications, including regional liver functional assessment and patient monitoring after therapy; however, more data are needed in some areas, and further developments are needed to translate cutting-edge techniques into clinical practice.

Key Points

• Liver-specific MRI is a fast-growing field, with many technological and protocol advancements.

• Gadoxetic acid-enhanced MRI demonstrates value for detecting and characterizing focal liver lesions.

• Gadoxetic acid-enhanced MRI shows promise in regional functional assessment and patient monitoring.

• Further developments are needed to translate cutting-edge techniques into clinical practice.

Usefulness of controlled aliasing in parallel imaging results in higher acceleration in gadoxetic acid-enhanced liver magnetic resonance imaging to clarify the hepatic arterial phase

PURPOSE

We aimed to determine whether the controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) technique could improve the image quality of the hepatic arterial phase of gadoxetic acid-enhanced liver magnetic resonance (MR) imaging.

MATERIALS AND METHODS

A total of 320 patients underwent gadoxetic acid-enhanced liver MR imaging: a conventional protocol (a fixed scan delay and 2-mL/s injection) using a standard 3-T MR system (Trio-Tim; Siemens, commercialized since 2005) (group A), an optimized protocol (bolus tracking and 1-mL/s injection) using a standard 3-T MR (group B), an optimized protocol using a new 3-T MR (Skyra; Siemens, commercialized since 2012) (group C), and an optimized protocol with CAIPIRINHA using a new 3-T MR (group D). The image quality of the hepatic arterial phase was graded using a 4-point rating scale from 1 (no artifacts) to 4 points (non-diagnostic images with severe artifacts). The differences in image quality scores among the 4 groups were evaluated. In addition, the detection rates of hypervascular hepatocellular carcinomas among the 4 groups were evaluated.

RESULTS

Scores of 4 points were observed in groups A (n = 7), B (n = 5), and C (n = 3) but not in group D. The median image quality score was 2 in groups A and B and 1 in groups C and D. From group A to group D, the median image quality score decreased significantly (P = 0.0001). The median image quality score was significantly lower in group D than in groups A and B (P = 0.0001 and 0.001, respectively), whereas there was no significant difference observed between groups C and D (P = 0.656). The detection rates of hypervascular hepatocellular carcinomas on the hepatic arterial phase were not significantly different among the groups (all P > 0.03), except between groups A and D (P = 0.007).

CONCLUSIONS

The CAIPIRINHA technique improved the image quality of hepatic arterial phase imaging with gadoxetic acid, reducing the number of non-diagnostic arterial phase studies.

CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects

Computed tomography (CT) and magnetic resonance (MR) imaging play critical roles in the diagnosis and staging of hepatocellular carcinoma (HCC). The first article of this two-part review discusses key concepts of HCC development, growth, and spread, emphasizing those features with imaging correlates and hence most relevant to radiologists; state-of-the-art CT and MR imaging technique with extracellular and hepatobiliary contrast agents; and the imaging appearance of precursor nodules that eventually may transform into overt HCC.

Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium

PURPOSE

To determine, in a dual-center setting, whether patients who experience transient severe motion ( TSM transient severe motion ) in the arterial phase during gadoxetate disodium-enhanced magnetic resonance (MR) imaging are at higher risk for a subsequent episode of TSM transient severe motion than patients who do not have TSM transient severe motion during initial gadoxetate disodium administration.

MATERIALS AND METHODS

Institutional review board approval was obtained for this retrospective, multi-institutional HIPAA-compliant study. The requirement for informed consent was waived. One hundred seventy patients each underwent two MR imaging examinations with bolus injection of gadoxetate disodium at one of two sites. Three radiologists reviewed the examinations at each site for TSM transient severe motion , based on severe arterial phase motion, despite minimal motion in the other dynamic phases. The occurrence rate of TSM transient severe motion in the second examination was compared between patients who had TSM transient severe motion in their first examination and those who did not by using the χ(2) or Fisher exact test, as appropriate. Relative risks and 95% confidence intervals ( CI confidence interval s) were calculated.

RESULTS

TSM transient severe motion rates in second examinations were significantly higher for patients who had TSM transient severe motion in their first examination: site 1, 67% (six of nine) vs 4% (three of 69) (P < .0001); site 2, 60% (three of five) vs 6% (five of 87) (P < .005); and both sites, 64% (nine of 14) vs 5% (eight of 156) (P < .0001). Relative risks were 15 for site 1 (95% CI confidence interval : 5, 51), 10 for site 2 (95% CI confidence interval : 3, 32), and 13 for both sites (95% CI confidence interval : 6, 27).

CONCLUSION

Patients who experience TSM transient severe motion during gadoxetate disodium-enhanced MR imaging are at significantly and substantially higher risk for TSM transient severe motion in the next gadoxetate disodium-enhanced examination compared with patients who do not have TSM transient severe motion during their initial gadoxetate disodium administration.

Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma

Hepatocellular carcinoma (HCC) develops via multistep hepatocarcinogenesis, during which hypovascular/early HCC precedes the typical hypervascular HCC. The hypovascular HCC lacks the typical hallmark imaging features of HCC, such as late arterial phase enhancement and portal venous washout, limiting early detection using conventional extracellular contrast agents for dynamic magnetic resonance imaging (MRI) or computed tomography (CT) imaging. In recent years, gadolinium-based contrast agents with hepatobiliary uptake have garnered interest from radiologists and hepatologists due to their potential for improved detection of HCC during hepatobiliary phase MRI. Lesions with reduced or absent hepatocyte function appear hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI. This behavior can be exploited for earlier detection of hypovascular HCC. This review describes the general characteristics and advantages of gadoxetic acid for the diagnosis of HCC with a particular focus on hypovascular/early HCC.

Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine

PURPOSE

To compare frequency and severity of arterial phase respiratory motion-related artifact following gadoxetate disodium and gadobenate dimeglumine in matched patients administered both contrast media at different times.

MATERIALS AND METHODS

Institutional review board approval was obtained, with patient consent waived, for this retrospective, HIPAA-compliant study. Ninety patients underwent gadobenate dimeglumine-enhanced abdominal magnetic resonance (MR) followed by gadoxetate disodium-enhanced abdominal MR and were matched to 90 patients who were administered the same contrast media in reverse order (180 patients). Matching was based on length of time between paired examinations. Gadobenate dimeglumine dose was weight based (0.1 mmol per kilogram body weight). Gadoxetate disodium dose was typically fixed (10 or 20 mL [off label]). Three readers blinded to contrast agent assigned a respiratory motion-related artifact score (1 [none] to 5 [nondiagnostic]) for nonenhanced, arterial, venous, and late dynamic phases. Frequency of greater new arterial phase respiratory motion-related artifact in each within-patient pair and aggregate rate of new severe transient arterial phase respiratory motion-related artifact (scores ≤ 2, nonenhanced and venous and/or late dynamic phases; ≥ 4, arterial phase) were compared (McNemar test).

RESULTS

For groups 1 and 2, respectively, mean dose (gadoxetate disodium, 16.6 mL vs 16.6 mL, P = .99; gadobenate dimeglumine, 18.0 mL vs 17.8 mL, P = .77) and mean time between examinations (191 days vs 191 days, P = .99) were not significantly different between matched populations. Gadoxetate disodium was associated with significantly higher incidence of new arterial phase respiratory motion-related artifact compared with gadobenate dimeglumine (39% vs 10%, P < .0001) and of new severe transient arterial phase respiratory motion-related artifact (18% vs 2%, P < .0001) in patients administered both agents at different times.

CONCLUSION

Fixed off-label dose (10 or 20 mL) of gadoxetate disodium is associated with arterial phase respiratory motion-related artifact that is sometimes severe and occurs significantly more often than after gadobenate dimeglumine in patients who received both contrast media.

Liver-specific agents for contrast-enhanced MRI: role in oncological imaging

Liver-specific magnetic resonance (MR) contrast agents are increasingly used in evaluation of the liver. They are effective in detection and morphological characterization of lesions, and can be useful for evaluation of biliary tree anatomy and liver function. The typical appearances and imaging pitfalls of various tumours at MR imaging performed with these agents can be understood by the interplay of pharmacokinetics of these contrast agents and transporter expression of the tumour. This review focuses on the applications of these agents in oncological imaging.

The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase

Hepatocyte specific contrast agents including gadoxetic acid and gadobenate dimeglumine are very useful to diagnose various benign and malignant focal hepatic lesions and even helpful to estimate hepatic functional reservoir. The far delayed phase image referred to as the hepatobiliary phase makes the sensitivity of detection for malignant focal hepatic lesions increased, but specificity of malignant diseases, including hepatocellular carcinoma, metastasis and cholangiocarcinoma, characterization remained to be undetermined.

Time-intensity curve in the abdominal aorta on dynamic contrast-enhanced MRI with high temporal and spatial resolution: Gd-EOB-DTPA versus Gd-DTPA in vivo

PURPOSE

To evaluate the difference in the time-intensity curves (TICs) of the abdominal aorta on dynamic contrast-enhanced MRI (DCE-MRI) between Gd-DTPA and Gd-EOB-DTPA.

MATERIALS AND METHODS

Ten healthy volunteers underwent DCE-MRI three times with the following protocol: group A, Gd-DTPA at an injection rate of 3 ml/s; group B, Gd-EOB-DTPA, 3 ml/s; group C, Gd-EOB-DTPA, 1.5 ml/s. Signal intensities (SIs) of the abdominal aorta were measured, and the contrast enhancement ratio (CER) was calculated. Time-to-CER curves were compared among the three groups. The differences in maximum CER (CERmax) and time-to-peak of CER were analyzed.

RESULTS

The time-to-CER curve showed a double peak pattern in group A and single-peak pattern in groups B and C. The mean time between the first and the second peak was 6.2 s. The mean CERmax of each group was 4.50, 4.52 and 4.27, respectively. In group A, B and C, the mean time-to-peak was 14.6, 10.6 and 12.6 s, respectively. There was a significant difference between group A and B (P < 0.01).

CONCLUSION

To set up the optimal protocol for abdominal DCE-MRI, it should be noted that TIC in the Gd-DTPA and Gd-EOB-DTPA group showed different patterns, and a slower injection rate showed a less abrupt SI change in the Gd-EOB-DTPA group than in the Gd-DTPA group.